Clinical Trial

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-07; most recent amendment 2025-11-25.
Trial Details
NCT Number NCT06172205
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Enrollment 262 participants
Start Date 2023-07-01
Primary Completion 2028-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-03